Fibrolamellar Carcinoma News and Research

RSS
Gift boosts efforts to understand and combat rare cancers

Gift boosts efforts to understand and combat rare cancers

New grant to Harvard Medical School is boosting efforts to understand and combat rare cancers

New grant to Harvard Medical School is boosting efforts to understand and combat rare cancers

Researchers pinpoint treatment target for rare liver cancer in adolescents, young adults

Researchers pinpoint treatment target for rare liver cancer in adolescents, young adults

CASI reports financial results for second quarter 2015

CASI reports financial results for second quarter 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment